Mankind Pharma

Last updated

Mankind Pharma Limited
Company type Public
ISIN INE634S01028
Industry Pharmaceutical
Founded1991;33 years ago (1991)
Founders
Headquarters
Okhla Phase III, Delhi
,
India [2]
Area served
Worldwide
Key people
  • Ramesh Juneja (Chairman)
  • Rajeev Juneja (MD & Vice Chairman)
  • Sheetal Arora (CEO)
  • Arjun Juneja (COO)
Products
RevenueIncrease2.svg₹10,335 crore (US$1.2 billion) (FY24) [3]
Increase2.svg₹2,550 crore (US$310 million) (FY24) [3]
Increase2.svg₹1,942 crore (US$230 million) (FY24) [3]
Number of employees
22,000+ (2023) [4]
Website www.mankindpharma.com OOjs UI icon edit-ltr-progressive.svg

Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. [5] [6] [7]

Contents

As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. [8] The company derived 97% of its operating revenue from the Indian market, [9] where it is reportedly the fourth largest pharmaceutical company by domestic sales. [8] Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, [10] Prega News in pregnancy test kits, [11] and Unwanted-72 in emergency contraception. [12]

History

Mankind Pharma was incorporated in 1991, and actively started its operations in 1995, with the contributions of two brothers, Ramesh C. Juneja and Rajeev Juneja, who established the company with a seed capital of ₹ 5,000,000. [13] [14] The company was started with 20 employees and launched in two states in the first year of its operation. [15] [16]

Mankind Pharma initially targeted price-sensitive drugs, with a focus on rural market; [17] its early products included antibacterial drug Zenflox and prescription antibiotic Moxikind CV, which were priced at a steep discount to the existing products in the market. [18] The company ventured into the over-the-counter segment in 2007, focusing primarily on sexual healthcare products. [19] [20]

Prega News livery on a SpiceJet aircraft. Spicejet 737-800 special livery "Prega News" at Bangalore Airport (38764400805).jpg
Prega News livery on a SpiceJet aircraft.

The company acquired Magnet Labs Pvt. Ltd. to enter the antipsychotic segment in 2007. [21] It acquired Longifene-an appetite stimulant for children in January 2010 which was earlier a brand of UCB. [22]

In 2017, Mankind Pharma established Pathkind Labs, a provider of diagnostics and healthcare tests. [23]

In 2019, Mankind became the first Indian company and second only in the world to develop and launch Dydrogesterone, a drug used in high-risk pregnancies and infertility by the brand name Dydroboon. [24]

In 2022, Mankind acquired Panacea Biotec Pharma's domestic formulations brands in India and Nepal for ₹1,872 crore (US$220 million). [25] It then acquired a respiratory treatment product, and an infant skincare brand from Dr. Reddy's Laboratories. [26] It also bought a majority stake in the Ayurvedic and herbal products manufacturer, Upakarma Ayurveda. [27]

In 2022, the company entered agritech [28] and pet care segments. [29]

In April 2023, Mankind Pharma launched its initial public offering (IPO), with existing investors selling ₹4,326 crore (US$520 million) worth of shares. [30]

In 2024, Mankind Pharma acquired a 100% stake in Bharat Serums and Vaccines (BSV) from private equity firm Advent International for an enterprise value of ₹13,630 crore (US$1.6 billion). [31] The deal included over 2,500 employees joining the company. Mankind also aimed to raise up to ₹10,000 crore through non-convertible debentures to support its growth initiatives. [31]

As per Forbes list of India’s 100 richest tycoons, dated OCTOBER 09, 2024, Ramesh and Rajeev Juneja & family are ranked 42nd with a net worth of $7 Billion. [32]

See also

Related Research Articles

<span class="mw-page-title-main">Cipla</span> Indian multinational pharmaceutical company

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Hetero Drugs</span> An Indian pharmaceutical company

Hetero Drugs is an Indian pharmaceutical company and the world's largest producer of anti-retroviral drugs. Hetero's business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

<span class="mw-page-title-main">Emami</span> Indian multinational conglomerate

Emami Group is an Indian multinational conglomerate headquartered in Kolkata. The company caters to a number of niche categories in the personal care and healthcare segments.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Elder Pharmaceuticals</span> Indian pharmaceutical company

Elder Pharmaceuticals Ltd is a pharmaceutical company headquartered in Mumbai, Maharashtra. Its main activities include the manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices. Its largest presence in three therapeutic segments, Women's Healthcare, Wound Care and Nutraceuticals. It has 6 manufacturing plants in India & 1 in Nepal. It manufacture various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 22 manufacturing plants, 17 in India and the rest in Greece, United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India. Its market presence is in more than 100+ countries.

Snapdeal is an Indian e-commerce company, based in New Delhi, India. It was founded in February 2010 by Kunal Bahl and Rohit Bansal.

<span class="mw-page-title-main">Ramesh Juneja</span> Indian businessperson (born 1955)

Ramesh C. Juneja is an Indian billionaire businessman and the Chairman of Mankind Pharma. He is one of the 100 richest Indians as per Forbes; his net worth was estimated to be $2.3 billion in 2019.

<span class="mw-page-title-main">Piramal Group</span> Indian conglomerate

The Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate.

<span class="mw-page-title-main">Cadila Pharmaceuticals</span> Indian pharmaceutical company

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.

OYO Rooms, also known as OYO Hotels & Homes, is an Indian multinational hospitality chain of leased and franchised hotels, homes, and living spaces. Founded in 2012 by Ritesh Agarwal, OYO initially consisted mainly of budget hotels. As of January 2020, it has more than 43,000 properties and 1 million rooms across 800 cities in 80 countries.

FSN E-Commerce Ventures Ltd, d/b/a Nykaa, is an Indian retail company, headquartered in Mumbai. It sells beauty, wellness and fashion products through its website, mobile app and over 100 physical stores. In 2020, it became the first Indian unicorn startup headed by a woman.

<span class="mw-page-title-main">Laurus Labs</span> Indian pharmaceutical company

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology, veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava.

<span class="mw-page-title-main">Zydus Wellness</span> Indian consumer goods company

Zydus Wellness is an Indian consumer goods company headquartered in Ahmedabad, which produces nutrition and skincare products. It is a subsidiary of the pharmaceutical company Zydus Lifesciences. Its brands include Glucon-D, Sugar Free, EverYuth, Complan, and Nycil. The company operates three manufacturing plants, one in Gujarat and 2 in Sikkim.

PharmEasy is an Indian e-pharmacy company that sells medicines, diagnostics and telehealth online.

<span class="mw-page-title-main">Indigo Paints</span> Indian paint company

Indigo Paints Limited is an Indian paint company that is headquartered in Pune, Maharashtra, and has five manufacturing facilities that are located at Jodhpur, Kochi and Pudukkottai. The company is engaged in manufacturing, selling and distribution of decorative paints, Emulsion, enamels, waterproofing & chemical constructions, wood coatings, distemper, primers, putties and cement paints.

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO) that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on August 6, 2024.

References

  1. ↑ Bhalla, Mohit; Rajagopal, Divya. "Mankind Pharma: The story of Juneja siblings, the biggest disruptors in Indian pharma space". The Economic Times. Retrieved 21 December 2022.
  2. ↑ Singh, Khomba. "Mankind Pharma's pocket-friendly pricing in demand". The Economic Times. Retrieved 21 December 2022.
  3. 1 2 3 "Investor Presentation Q4FY24" (PDF). Mankind Pharma. Retrieved 15 May 2024.
  4. ↑ "Mankind Pharma Forays Into Critical Care Segment". Outlook India. Retrieved 12 April 2023.
  5. ↑ "India's Mankind Pharma wants deals, sees FY domestic sales topping $700 mln". Reuters. 10 April 2015. Retrieved 21 March 2023.
  6. ↑ Raturi, Prerna (11 February 2012). "For a robust business". Business Standard. Archived from the original on 27 April 2012. Retrieved 7 May 2023.
  7. ↑ Singh, Raveena (20 March 2023). "At $6-7B, Mankind Pharma eyes Torrent's valuation. But its catch lies in Eris & Gland IPOs". The Ken. Retrieved 21 March 2023.
  8. 1 2 Raghunathan, Anu (11 October 2023). "Mankind Pharma's Founders Map Growth Plan After Pulling Off Major IPO". Forbes. Retrieved 4 December 2023.
  9. ↑ "India's biggest condom maker lifts dreary IPO market". Financial Times. 27 April 2023. Retrieved 4 December 2023.
  10. ↑ Tandon, Suneera (18 February 2022). "Durex becomes second-largest condom brand in India: Reckitt". Mint. Retrieved 22 November 2022.
  11. ↑ "Behind Mankind's plans to take Prega News to rural markets". Moneycontrol. Retrieved 22 November 2022.
  12. ↑ "Mankind Pharma Ltd" (PDF). Geojit. Retrieved 24 April 2023.
  13. ↑ Hussain, Shabana (8 May 2014). "Mankind Pharma: Formulating Strategy To Enter The Big League" . Retrieved 27 June 2018.
  14. ↑ "Mankind Pharma set to tap core drugs market". Business Standard. 19 July 2012. Archived from the original on 6 October 2014. Retrieved 26 April 2023.
  15. ↑ "A Giant Leap For Mankind". Business Outlook India. 24 December 2011. Archived from the original on 29 June 2012. Retrieved 5 February 2013.
  16. ↑ "Testing Times For Mankind Pharma". Businessworld. Retrieved 26 April 2023.
  17. ↑ Rajagopal, Divya (13 June 2012). "How Ramesh Juneja's Mankind Pharma has changed pharma game with pulp marketing". The Economic Times. Retrieved 1 March 2023.
  18. ↑ "Mankind vs Goliaths". Business Standard. 3 November 2009. Retrieved 26 April 2023.
  19. ↑ Singh, Khomba (3 March 2007). "Mankind forays into OTC market". The Economic Times. Retrieved 27 April 2023.
  20. ↑ Singh, Rajiv (26 March 2014). "Mankind Pharma: Do products revolving around sex help the Rs 3000 cr company?". The Economic Times. Retrieved 26 April 2023.
  21. ↑ "Acquisition of Magnet Labs" (PDF). The International Journal of Business Management and Technology. ISSN   2581-3889.[ permanent dead link ]
  22. ↑ Mankind Pharma markets Longifene- 29 August 2011
  23. ↑ "Mankind Pharma forays into diagnostics". The Times of India. 31 March 2017. Retrieved 26 April 2023.
  24. ↑ "Mankind Pharma launches drug for the treatment of infertility in India". The Economic Times. Retrieved 22 November 2022.
  25. ↑ "Mankind Pharma acquires Panacea's domestic formulation brands for Rs 1,872 cr". Business Today. 1 March 2022. Retrieved 22 November 2022.
  26. ↑ "Mankind Pharma acquires two derma and respiratory brands from Dr. Reddy's". Business Standard. Retrieved 22 November 2022.
  27. ↑ Mahtta, Priyal (28 November 2022). "Mankind Pharma acquires majority stake in Upakarma Ayurveda". mint. Retrieved 3 December 2022.
  28. ↑ "Mankind Pharma forays into agri-tech space, plans to invest Rs 200 crore". Business Standard. 5 April 2022. Retrieved 1 March 2023.
  29. ↑ Pilla, Viswanath (21 December 2022). "Mankind Pharma enters pet care segment with launch PetStar brand". The Economic Times. Retrieved 1 March 2023.
  30. ↑ Prabhakar, Sai (22 April 2023). "Mankind Pharma IPO: Why it's a promising prescription". The Hindu Businessline. Retrieved 26 April 2023.
  31. 1 2 Das, Sohini (26 July 2024). "Mankind Pharma acquires Bharat Serums and Vaccines for Rs 13,600 crore". Business Standard. Retrieved 9 August 2024.
  32. ↑ "India's 100 Richest". India’s 100 Richest. 9 October 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.